权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Vascular networks genetically engineered for protein drug delivery

用于蛋白质药物输送的基因工程血管网络

基本信息

批准号：
10617773
负责人：
Minglin Ma
金额：
$ 66.71万
依托单位：
BOSTON CHILDREN'S HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-08-15 至 2025-04-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10617773
关键词：
3-Dimensional Activated Partial Thromboplastin Time measurement Address Alginates Allogenic Biological Assay Biology Bioluminescence Blood Blood Circulation Blood Coagulation Disorders Blood Vessels Blood coagulation Canis familiaris Cell Line Cell Survival Cell Transplantation Cells Clinical Clone Cells Coagulation Process Code Competence Cytoprotection DNA Transposons Data Dermal Development Devices Diameter Disease Drug Delivery Systems Eligibility Determination Encapsulated Endothelial Cells Engineering Engraftment Enzyme-Linked Immunosorbent Assay Enzymes Evaluation Excision Exons Extracellular Matrix F8 gene Factor VIII Fibrinogen Fibroblasts Future Genetic Engineering Genome Genomics Germ Cells Greater sac of peritoneum Hemophilia A Hemorrhage Homologous Transplantation Human Hydrogels Immune Immunocompetent Immunologic Deficiency Syndromes In Vitro Inflammation Infusion procedures Inherited Internal Ribosome Entry Site Length Life Liver Maps Methods Morbidity - disease rate Mus Mutation Organoids Patients Phenotype Plasma Pluripotent Stem Cells Production Productivity Protein Engineering Research Risk Safety System Tail Technology Teratoma Testing Therapeutic Time Titrations Transgenes Translations Transplantation Transposase Tubular formation United States National Institutes of Health Vascularization White Blood Cell Count procedure Whole Blood Work clinically relevant density experience gene therapy human pluripotent stem cell immunoreaction implantation in vivo induced pluripotent stem cell inhibitor new technology novel preclinical efficacy prevent programs response sensor subcutaneous

项目摘要

PROJECT SUMMARY/ABSTRACT Hemophilia A is an inherited bleeding disorder caused by mutations in the F8 gene encoding coagulation factor VIII (FVIII). Current treatment involves repeated i.v. infusions of FVIII concentrates throughout the life of the patient, which creates tremendous discomfort and morbidity. Alternatively, we seek to develop a novel technology for sustained FVIII delivery. Recently, we developed a non-viral ex vivo gene therapy approach for hemophilia A. We used a piggyBac DNA transposon system to insert 70 copies of the F8 gene into human pluripotent stem cells (PSCs). We differentiated these modified F8-PSCs into endothelial cells (iECs; natural producers of FVIII) and demonstrated the production of exceedingly high levels of FVIII. After subcutaneous engraftment of our human F8-iECs into immunodeficient hemophilic (SCID-f8ko) mice, we achieved up to 600% circulating levels of FVIII, effectively correcting the clotting deficiency. Notwithstanding this progress, our open- graft approach has some inherent limitations for translation: 1) immune rejection of non-autologous cells, and 2) concerns over cell dissemination and safety. To address these limitations, we have teamed up with Dr. Minglin Ma (Cornell), who has extensive experience with devices for encapsulation and transplantation of cells in mice and dogs. We propose a technology entailing a novel retrievable encapsulation device. We will assemble our F8-iECs into stable 3D vascular organoids and will then embed multiple organoids into an alginate hydrogel inside a tubular encapsulation device (1-mm diameter; variable length). Based on our preliminary data, we hypothesize that our device will protect the cells from immune rejection and produce FVIII that will reach the bloodstream at therapeutic levels upon implantation into the peritoneal cavity. To test these hypotheses, we propose three Specific Aims. In Aim-1, we will genetically engineer vascular organoids for the production of clinically relevant levels of FVIII. We will develop a new promoterless exon-trap sensor cassette to avoid intra- exon integration of our piggyBac transposon. We will then insert multiple F8 copies into NIH-eligible PSC lines to generate universal clones for high FVIII production. In Aim-2, we will establish an encapsulation device configuration for optimal FVIII production and determine the safety and long-term efficacy in immunocompetent hemophilic mice. We will evaluate cell survival, BDD-FVIII activity in plasma, correction of coagulation deficiency, risk of teratoma formation, and reversibility of the treatment. In Aim-3, we will evaluate the safety and long-term efficacy of our devices in dogs. We will first generate canine-specific FVIII-secreting vascular organoids. We will then transplant our devices (I.P.) in healthy dogs for up to 6 months and evaluate scalability, safety, retrievability, and FVIII production. Lastly, we will test our allogeneic devices in hemophilia A dogs and establish safety and efficacy for up to 1 year. In summary, we propose studies to develop a novel technology to deliver FVIII in hemophilia A. We envision this research could pave the way for future studies in humans.

项目总结/文摘